Insmed (NASDAQ:INSM) versus Anthera Pharmaceuticals (OTCMKTS:ANTH) Financial Review

Anthera Pharmaceuticals (OTCMKTS:ANTH) and Insmed (NASDAQ:INSM) are both healthcare companies, but which is the superior business? We will contrast the two companies based on the strength of their analyst recommendations, valuation, risk, institutional ownership, dividends, profitability and earnings.

Analyst Ratings

This is a breakdown of current ratings and price targets for Anthera Pharmaceuticals and Insmed, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Anthera Pharmaceuticals	0	0	0	0	0.00
Insmed	1	0	23	2	3.00

Insmed has a consensus target price of $205.52, indicating a potential upside of 55.03%. Given Insmed’s stronger consensus rating and higher probable upside, analysts plainly believe Insmed is more favorable than Anthera Pharmaceuticals.

Profitability

This table compares Anthera Pharmaceuticals and Insmed’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Anthera Pharmaceuticals	N/A	N/A	N/A
Insmed	-76.94%	-123.94%	-44.30%

Risk & Volatility

Anthera Pharmaceuticals has a beta of 0.39, suggesting that its stock price is 61% less volatile than the S&P 500. Comparatively, Insmed has a beta of 0.81, suggesting that its stock price is 19% less volatile than the S&P 500.

Earnings and Valuation

This table compares Anthera Pharmaceuticals and Insmed”s revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Anthera Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
Insmed	$606.42 million	47.74	-$1.28 billion	($4.11)	-32.26

Anthera Pharmaceuticals has higher earnings, but lower revenue than Insmed.

Summary

Insmed beats Anthera Pharmaceuticals on 6 of the 9 factors compared between the two stocks.

About Anthera Pharmaceuticals

Anthera Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of medicines for patients with unmet medical needs. It develops Sollpura, a non-porcine investigational pancreatic enzyme replacement therapy that is in Phase III clinical trial for the treatment of patients with exocrine pancreatic insufficiency; and Blisibimod, which is in Phase II clinical trial for the treatment of B-cell mediated autoimmune diseases, including immunoglobulin A nephropathy or IgA nephropathy. The company has license agreements with Amgen, Inc., and Eli Lilly and Company. Anthera Pharmaceuticals, Inc. was founded in 2004 and is based in Houston, Texas.

About Insmed

Insmed Incorporated is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Insmed’s first commercial product is ARIKAYCE® (amikacin liposome inhalation suspension), which is approved in the United States for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options. MAC lung disease is a rare and often chronic infection that can cause irreversible lung damage and can be fatal. Insmed’s earlier-stage clinical pipeline includes INS1007, a novel oral reversible inhibitor of dipeptidyl peptidase 1 with therapeutic potential in non-cystic fibrosis bronchiectasis and other inflammatory diseases, and INS1009, an inhaled formulation of a treprostinil prodrug that may offer a differentiated product profile for rare pulmonary disorders, including pulmonary arterial hypertension.